Helio Sader

Senior Director for Microbiology and Surveillance @ JMI Laboratories

[JMI Laboratories @jmilabs]

.@HelioSader's most recent article out @BSACandJAC:

Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018–19)

https://t.co/xWZrtvoykU

[Helio Sader @HelioSader]

It's been a busy few months. A few weeks ago on May 17 I presented "New BL/BLI Combos against Pseudomonas aeruginosa and Enterobacterales from Patients with Pneumonia in Intensive Care Units" at @atscommunity https://t.co/iRlvAeJRBk

[Helio Sader @HelioSader]

Thank you!

[Alex Lepak @a_lepak]

@cjcrnich1 @OncIDPharmd @wfwrighID @heliosader @mcastanheirajmi have a nice article of complexity ceftaz-avi resistance in PsA too!!!

[Helio Sader @HelioSader]

From "Antimicrobial Susceptibility of Organisms Isolates from Complicated UTI in Europe: Results from the SENTRY Antimicrobial Surveillance Program (2019-2021)" @jmilabs #ECCMID2022

See the full presentation here:
https://t.co/MLB1mz5nxk

[Helio Sader @HelioSader]

From "Bloodstream infections in Europe: Aetiology and Antimicrobial Susceptibility Results from the SENTRY Antimicrobial Surveillance Program (2019-2021)" @jmilabs #ECCMID2022

See the full presentation here:
https://t.co/YBs6VRqEEN

[Helio Sader @HelioSader]

From "Lefamulin Activity against Bacterial Pathogens Typically Causing Pneumonia Collected from European Medical Centres in 2020 and 2021" @nabriva #ECCMID2022

See the full presentation here:
https://t.co/T46wZUeSwK

[Helio Sader @HelioSader]

From "Lefamulin Activity against a Contemporary Global Collection of Staphylococcus aureus (SENTRY 2020-2021)" @nabriva #ECCMID2022

See the full presentation here:
https://t.co/dUL89dM6kR

[Helio Sader @HelioSader]

From "Antimicrobial Activity of Aztreonam-avibactam and Comparator Agents against Ceftazidime-avibactam-resistant Enterobacterales (2019-2021)" @pfizer #eccmid2022

See the full presentation here:
https://t.co/0ep3h7yQvb

[Helio Sader @HelioSader]

From "Antimicrobial Activity of Dalbavancin and Comparators against Gram-positive Bacteria Causing Bacteraemia in Patients with Skin and Skin Structure Infections (2017-2021)" @abbvie #ECCMID2022

See the full presentation here:
https://t.co/D9E90Iukw7

[Helio Sader @HelioSader]

From "Antimicrobial Susceptibility of Enterobacterales Causing Infections in Intensive Care Unit Patients: The Role of New B-Lactamase Inhibitor Combinations" @abbvie #ECCMID2022

See the full presentation here:
https://t.co/Hx9fFIFjxy

[Helio Sader @HelioSader]

From "Comparative Activity of Newer B-lactam/B-lactamase Inhibitor Combinations against Pseudomonas aeruginosa from Patients in ICUs of US Medical Centres in 2021" @abbvie #ECCMID2022

See the full presentation here: https://t.co/5akIYKkBPY

[Helio Sader @HelioSader]

I'll tweet snippets from my #ECCMID2022 posters over the next few days. Research was supported by @abbvie, @jmilabs, @nabriva, and @pfizer.

[Helio Sader @HelioSader]

Hello! I'll be in Lisbon for #ECCMID2022 with @jmilabs. Here's a list of my posters and presentations. Love to see you there.